The Tyrosine Protein Kinase JAK2 pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase JAK2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Tyrosine Protein Kinase JAK2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Dermatology, and Respiratory which include the indications Myelofibrosis, Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis), Graft Versus Host Disease (GVHD), Inflammation, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, Asthma, and Chronic Obstructive Pulmonary Disease (COPD). It also reviews key players involved in Tyrosine Protein Kinase JAK2 targeted therapeutics development with respective active and dormant or discontinued products.
The Tyrosine Protein Kinase JAK2 pipeline targets constitutes close to 47 molecules. Out of which, approximately 36 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, and Discovery stages are 7, 2, 5, 4, 3, 1, 6, and 8 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 6, and 5 molecule.
Tyrosine Protein Kinase JAK2 overview
Janus kinase 2 is a non-receptor tyrosine kinase. It is involved in various processes such as cell growth, development, differentiation or histone modifications. It mediates essential signaling events in both innate and adaptive immunity. It plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone, prolactin, leptin, erythropoietin, thrombopoietin or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. It plays a role in cell cycle by phosphorylating CDKN1B.
For a complete picture of Tyrosine Protein Kinase JAK2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
